| Identification | Back Directory | [Name]
REVEROMYCIN A | [CAS]
134615-37-5 | [Synonyms]
REVEROMYCIN A
ZESGNAJSBDILTB-OXVOKJAASA-N
Butanedioic acid, 1-[(2S,3R,6S,8R,9S)-3-butyl-8-[(2E,4E,6S,7S,8E)-9-carboxy-6-hydroxy-3,7-dimethyl-2,4,8-nonatrien-1-yl]-2-[(1E,3E)-4-carboxy-3-methyl-1,3-butadien-1-yl]-9-methyl-1,7-dioxaspiro[5.5]undec-3-yl] ester | [Molecular Formula]
C36H52O11 | [MDL Number]
MFCD00912537 | [MOL File]
134615-37-5.mol | [Molecular Weight]
660.79 |
| Chemical Properties | Back Directory | [Boiling point ]
849.0±65.0 °C(Predicted) | [density ]
1.21±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C
| [solubility ]
DMF: soluble
| [form ]
solid
| [pka]
4.36±0.17(Predicted) | [color ]
tan |
| Hazard Information | Back Directory | [Uses]
Reveromycin A, the dominant analogue of a complex of spiroketals isolated from a Streptomyces sp., is an inhibitor of the mitogenic activity of EGF. Reveromycin A is a G1 phase cell cycle inhibitor, selectively inhibiting isoleucyl-tRNA synthetase. Reveromycin A displays antiproliferative behaviour against human cell lines KB and K562, as well as potent antifungal activity. More recently it has been shown to induce apoptosis in osteoclasts thus inhibiting bone resorption. | [in vivo]
Reveromycin A (20 mg/kg; twice daily; i.v.; for 3 days) significantly decreases numbers of OCs without affecting numbers of osteoblasts in normal 4-week-old male Sprague-Dawley rats[2].
|
|
| Company Name: |
Lynnchem
|
| Telephone: |
86-(0)29-85992781 17792393971 |
| Website: |
http://www.lynnchem.com/ |
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
|